Year |
Citation |
Score |
2018 |
Monks A, Zhao Y, Hose C, Hamed H, Krushkal J, Fang J, Sonkin D, Palmisano A, Polley EC, Fogli LK, Konaté MM, Miller SB, Simpson MA, Voth AR, Li MC, et al. The NCI Transcriptional Pharmacodynamics Workbench: a tool to examine dynamic expression profiling of therapeutic response in the NCI-60 cell line panel. Cancer Research. PMID 30355619 DOI: 10.1158/0008-5472.Can-18-0989 |
0.443 |
|
2016 |
Zhang G, Park MA, Mitchell C, Walker T, Hamed H, Studer E, Graf M, Rahmani M, Gupta S, Hylemon PB, Fisher PB, Grant S, Dent P. Multiple cyclin kinase inhibitors promote bile acid-induced apoptosis and autophagy in primary hepatocytes via p53-CD95-dependent signaling. The Journal of Biological Chemistry. 291: 20823. PMID 27664064 DOI: 10.1074/jbc.A116.803444 |
0.756 |
|
2015 |
Tavallai M, Hamed HA, Roberts JL, Cruickshanks N, Chuckalovcak J, Poklepovic A, Booth L, Dent P. Nexavar/Stivarga and viagra interact to kill tumor cells. Journal of Cellular Physiology. 230: 2281-98. PMID 25704960 DOI: 10.1002/Jcp.24961 |
0.691 |
|
2015 |
Hamed HA, Tavallai S, Grant S, Poklepovic A, Dent P. Sorafenib/regorafenib and lapatinib interact to kill CNS tumor cells. Journal of Cellular Physiology. 230: 131-9. PMID 24911215 DOI: 10.1002/Jcp.24689 |
0.709 |
|
2014 |
Tavallai S, Hamed HA, Grant S, Poklepovic A, Dent P. Pazopanib and HDAC inhibitors interact to kill sarcoma cells. Cancer Biology & Therapy. 15: 578-85. PMID 24556916 DOI: 10.4161/Cbt.28163 |
0.645 |
|
2014 |
Bhatia S, Emdad L, Das SK, Hamed H, Dent P, Sarkar D, Fisher PB. Non-BRAF targeted therapies for melanoma: protein kinase inhibitors in Phase II clinical trials. Expert Opinion On Investigational Drugs. 23: 489-500. PMID 24502370 DOI: 10.1517/13543784.2014.884558 |
0.482 |
|
2014 |
Booth LA, Tavallai S, Hamed HA, Cruickshanks N, Dent P. The role of cell signalling in the crosstalk between autophagy and apoptosis. Cellular Signalling. 26: 549-55. PMID 24308968 DOI: 10.1016/J.Cellsig.2013.11.028 |
0.554 |
|
2014 |
Cruickshanks NA, Hamed HA, Booth LA, Tavallai S, Sajithlal GB, Grant S, Poklepovic A, Dent P. Abstract 796: Histone deacetylase inhibitors restore toxic BH3 domain protein expression in anoikis-resistant mammary and brain cancer stem cells, thereby enhancing the response to anti-ERBB1/ERBB2 therapy Cancer Research. 74: 796-796. DOI: 10.1158/1538-7445.Am2014-796 |
0.648 |
|
2014 |
Booth LA, Cruickshanks NA, Sajithlal GB, Hamed HA, Tavallai S, Syed J, Grant S, Poklepovic A, Dent P. Abstract 2690: Sorafenib/regorafenib and phosphatidyl inositol 3 kinase/thymoma viral proto-oncogene inhibition interact to kill tumor cells Cancer Research. 74: 2690-2690. DOI: 10.1158/1538-7445.Am2014-2690 |
0.732 |
|
2013 |
Hamed HA, Das SK, Sokhi UK, Park MA, Cruickshanks N, Archer K, Ogretmen B, Grant S, Sarkar D, Fisher PB, Dent P. Combining histone deacetylase inhibitors with MDA-7/IL-24 enhances killing of renal carcinoma cells. Cancer Biology & Therapy. 14: 1039-49. PMID 24025359 DOI: 10.4161/Cbt.26110 |
0.604 |
|
2013 |
Cruickshanks N, Hamed HA, Booth L, Tavallai S, Syed J, Sajithlal GB, Grant S, Poklepovic A, Dent P. Histone deacetylase inhibitors restore toxic BH3 domain protein expression in anoikis-resistant mammary and brain cancer stem cells, thereby enhancing the response to anti-ERBB1/ERBB2 therapy. Cancer Biology & Therapy. 14: 982-96. PMID 24025251 DOI: 10.4161/Cbt.26234 |
0.663 |
|
2013 |
Zhang Q, Raje V, Yakovlev VA, Yacoub A, Szczepanek K, Meier J, Derecka M, Chen Q, Hu Y, Sisler J, Hamed H, Lesnefsky EJ, Valerie K, Dent P, Larner AC. Mitochondrial localized Stat3 promotes breast cancer growth via phosphorylation of serine 727. The Journal of Biological Chemistry. 288: 31280-8. PMID 24019511 DOI: 10.1074/Jbc.M113.505057 |
0.614 |
|
2013 |
Sajithlal GB, Hamed HA, Cruickshanks N, Booth L, Tavallai S, Syed J, Grant S, Poklepovic A, Dent P. Sorafenib/regorafenib and phosphatidyl inositol 3 kinase/thymoma viral proto-oncogene inhibition interact to kill tumor cells. Molecular Pharmacology. 84: 562-71. PMID 23877009 DOI: 10.1124/Mol.113.088005 |
0.707 |
|
2013 |
Hamed HA, Yamaguchi Y, Fisher PB, Grant S, Dent P. Sorafenib and HDAC inhibitors synergize with TRAIL to kill tumor cells. Journal of Cellular Physiology. 228: 1996-2005. PMID 23674352 DOI: 10.1002/Jcp.24362 |
0.694 |
|
2013 |
Hamed HA, Yacoub A, Park MA, Archer K, Das SK, Sarkar D, Grant S, Fisher PB, Dent P. Histone deacetylase inhibitors interact with melanoma differentiation associated-7/interleukin-24 to kill primary human glioblastoma cells. Molecular Pharmacology. 84: 171-81. PMID 23661648 DOI: 10.1124/Mol.113.086553 |
0.58 |
|
2012 |
Cruickshanks N, Tang Y, Booth L, Hamed H, Grant S, Dent P. Lapatinib and obatoclax kill breast cancer cells through reactive oxygen species-dependent endoplasmic reticulum stress. Molecular Pharmacology. 82: 1217-29. PMID 22989520 DOI: 10.1124/Mol.112.081539 |
0.669 |
|
2012 |
Bareford MD, Hamed HA, Allegood J, Cruickshanks N, Poklepovic A, Park MA, Ogretmen B, Spiegel S, Grant S, Dent P. Sorafenib and pemetrexed toxicity in cancer cells is mediated via SRC-ERK signaling. Cancer Biology & Therapy. 13: 793-803. PMID 22673740 DOI: 10.4161/Cbt.20562 |
0.82 |
|
2012 |
Tang Y, Hamed HA, Poklepovic A, Dai Y, Grant S, Dent P. Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in mammary tumors. Molecular Pharmacology. 82: 322-32. PMID 22596349 DOI: 10.1124/Mol.112.078907 |
0.666 |
|
2012 |
Tang Y, Yacoub A, Hamed HA, Poklepovic A, Tye G, Grant S, Dent P. Sorafenib and HDAC inhibitors synergize to kill CNS tumor cells. Cancer Biology & Therapy. 13: 567-74. PMID 22406992 DOI: 10.4161/Cbt.19771 |
0.677 |
|
2012 |
Cruickshanks N, Hamed HA, Bareford MD, Poklepovic A, Fisher PB, Grant S, Dent P. Lapatinib and obatoclax kill tumor cells through blockade of ERBB1/3/4 and through inhibition of BCL-XL and MCL-1. Molecular Pharmacology. 81: 748-58. PMID 22357666 DOI: 10.1124/Mol.112.077586 |
0.82 |
|
2012 |
Booth L, Cazanave SC, Hamed HA, Yacoub A, Ogretmen B, Chen CS, Grant S, Dent P. OSU-03012 suppresses GRP78/BiP expression that causes PERK-dependent increases in tumor cell killing. Cancer Biology & Therapy. 13: 224-36. PMID 22354011 DOI: 10.4161/Cbt.13.4.18877 |
0.666 |
|
2012 |
Tang Y, Hamed HA, Cruickshanks N, Fisher PB, Grant S, Dent P. Obatoclax and lapatinib interact to induce toxic autophagy through NOXA. Molecular Pharmacology. 81: 527-40. PMID 22219388 DOI: 10.1124/Mol.111.076851 |
0.619 |
|
2012 |
Booth LA, Cruickshanks N, Tang Y, Bareford MD, Hamed HA, Fisher PB, Grant S, Dent P. Current advances in ER stress intervention therapies Endoplasmic Reticulum Stress in Health and Disease. 2147483647: 429-445. DOI: 10.1007/978-94-007-4351-9_19 |
0.753 |
|
2011 |
Bareford MD, Hamed HA, Tang Y, Cruickshanks N, Burow ME, Fisher PB, Moran RG, Nephew KP, Grant S, Dent P. Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells. Autophagy. 7: 1261-2. PMID 21814046 DOI: 10.4161/Auto.7.10.17029 |
0.823 |
|
2011 |
Mitchell C, Hamed HA, Cruickshanks N, Tang Y, Bareford MD, Hubbard N, Tye G, Yacoub A, Dai Y, Grant S, Dent P. Simultaneous exposure of transformed cells to SRC family inhibitors and CHK1 inhibitors causes cell death. Cancer Biology & Therapy. 12: 215-28. PMID 21642769 DOI: 10.4161/Cbt.12.3.16218 |
0.789 |
|
2011 |
Bareford MD, Park MA, Yacoub A, Hamed HA, Tang Y, Cruickshanks N, Eulitt P, Hubbard N, Tye G, Burow ME, Fisher PB, Moran RG, Nephew KP, Grant S, Dent P. Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells. Cancer Research. 71: 4955-67. PMID 21622715 DOI: 10.1158/0008-5472.Can-11-0898 |
0.824 |
|
2011 |
Park MA, Hamed HA, Mitchell C, Cruickshanks N, Dash R, Allegood J, Dmitriev IP, Tye G, Ogretmen B, Spiegel S, Yacoub A, Grant S, Curiel DT, Fisher PB, Dent P. A serotype 5/3 adenovirus expressing MDA-7/IL-24 infects renal carcinoma cells and promotes toxicity of agents that increase ROS and ceramide levels. Molecular Pharmacology. 79: 368-80. PMID 21119025 DOI: 10.1124/Mol.110.069484 |
0.727 |
|
2011 |
Bareford MD, Hamed HA, Park M, Grant S, Fisher P, Dent P. Abstract 5390: A serotype 5/3 adenovirus expressing MDA-7/IL-24 infects renal carcinoma cells and promotes toxicity of agents that increase ROS and ceramide levels Cancer Research. 71: 5390-5390. DOI: 10.1158/1538-7445.Am2011-5390 |
0.797 |
|
2011 |
Hamed HA, Mitchell C, Dent P, Yacoub A, Tye G, Bareford MD. Abstract 5383: Inhibition of MCL-1 in mammary and CNS tumor cells promotes cell deathin vitroandin vivo Cancer Research. 71: 5383-5383. DOI: 10.1158/1538-7445.Am2011-5383 |
0.799 |
|
2010 |
Dent P, Yacoub A, Hamed HA, Park MA, Dash R, Bhutia SK, Sarkar D, Wang XY, Gupta P, Emdad L, Lebedeva IV, Sauane M, Su ZZ, Rahmani M, Broaddus WC, et al. The development of MDA-7/IL-24 as a cancer therapeutic. Pharmacology & Therapeutics. 128: 375-84. PMID 20732354 DOI: 10.1016/J.Pharmthera.2010.08.001 |
0.527 |
|
2010 |
Dent P, Yacoub A, Hamed HA, Park MA, Dash R, Bhutia SK, Sarkar D, Gupta P, Emdad L, Lebedeva IV, Sauane M, Su ZZ, Rahmani M, Broaddus WC, Young HF, et al. MDA-7/IL-24 as a cancer therapeutic: from bench to bedside. Anti-Cancer Drugs. 21: 725-31. PMID 20613485 DOI: 10.1097/Cad.0B013E32833Cfbe1 |
0.563 |
|
2010 |
Hamed HA, Yacoub A, Park MA, Eulitt PJ, Dash R, Sarkar D, Dmitriev IP, Lesniak MS, Shah K, Grant S, Curiel DT, Fisher PB, Dent P. Inhibition of multiple protective signaling pathways and Ad.5/3 delivery enhances mda-7/IL-24 therapy of malignant glioma. Molecular Therapy : the Journal of the American Society of Gene Therapy. 18: 1130-42. PMID 20179672 DOI: 10.1038/Mt.2010.29 |
0.62 |
|
2010 |
Hamed HA, Yacoub A, Park MA, Eulitt P, Sarkar D, Dimitrie IP, Chen CS, Grant S, Curiel DT, Fisher PB, Dent P. OSU-03012 enhances Ad.7-induced GBM cell killing via ER stress and autophagy and by decreasing expression of mitochondrial protective proteins. Cancer Biology & Therapy. 9: 526-36. PMID 20107314 DOI: 10.4161/Cbt.9.7.11116 |
0.647 |
|
2010 |
Yacoub A, Hamed HA, Allegood J, Mitchell C, Spiegel S, Lesniak MS, Ogretmen B, Dash R, Sarkar D, Broaddus WC, Grant S, Curiel DT, Fisher PB, Dent P. PERK-dependent regulation of ceramide synthase 6 and thioredoxin play a key role in mda-7/IL-24-induced killing of primary human glioblastoma multiforme cells. Cancer Research. 70: 1120-9. PMID 20103619 DOI: 10.1158/0008-5472.Can-09-4043 |
0.744 |
|
2010 |
Yacoub A, Liu R, Park MA, Hamed HA, Dash R, Schramm DN, Sarkar D, Dimitriev IP, Bell JK, Grant S, Farrell NP, Curiel DT, Fisher PB, Dent P. Cisplatin enhances protein kinase R-like endoplasmic reticulum kinase- and CD95-dependent melanoma differentiation-associated gene-7/interleukin-24-induced killing in ovarian carcinoma cells. Molecular Pharmacology. 77: 298-310. PMID 19910452 DOI: 10.1124/Mol.109.061820 |
0.601 |
|
2010 |
Sisler JD, Szelag M, Potla R, Zhang Q, Szczepanek K, Derecka M, Wegrzyn J, Dulak J, Hamed H, Cichy J, Chen X, Baker DP, Dent P, Feldman GM, Shadel G, et al. PS1-58 The role of STAT1 in regulation of mitochondrial gene expression Cytokine. 52: 29-29. DOI: 10.1016/J.Cyto.2010.07.130 |
0.448 |
|
2009 |
Szelag M, Potla R, Sisler J, Hamed H, Dent P, Larner AC. STAT1 Expression represses the expression of mitochondrial encoded RNAS Cytokine. 48: 123-124. DOI: 10.1016/J.Cyto.2009.07.522 |
0.432 |
|
2008 |
Park MA, Zhang G, Mitchell C, Rahmani M, Hamed H, Hagan MP, Yacoub A, Curiel DT, Fisher PB, Grant S, Dent P. Mitogen-activated protein kinase kinase 1/2 inhibitors and 17-allylamino-17-demethoxygeldanamycin synergize to kill human gastrointestinal tumor cells in vitro via suppression of c-FLIP-s levels and activation of CD95. Molecular Cancer Therapeutics. 7: 2633-48. PMID 18790746 DOI: 10.1158/1535-7163.Mct-08-0400 |
0.766 |
|
2008 |
Park MA, Zhang G, Martin AP, Hamed H, Mitchell C, Hylemon PB, Graf M, Rahmani M, Ryan K, Liu X, Spiegel S, Norris J, Fisher PB, Grant S, Dent P. Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation. Cancer Biology & Therapy. 7: 1648-62. PMID 18787411 DOI: 10.4161/Cbt.7.10.6623 |
0.735 |
|
2008 |
Zhang G, Park MA, Mitchell C, Hamed H, Rahmani M, Martin AP, Curiel DT, Yacoub A, Graf M, Lee R, Roberts JD, Fisher PB, Grant S, Dent P. Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 5385-99. PMID 18765530 DOI: 10.1158/1078-0432.Ccr-08-0469 |
0.773 |
|
2008 |
Zhang G, Park MA, Mitchell C, Walker T, Hamed H, Studer E, Graf M, Rahmani M, Gupta S, Hylemon PB, Fisher PB, Grant S, Dent P. Multiple cyclin kinase inhibitors promote bile acid-induced apoptosis and autophagy in primary hepatocytes via p53-CD95-dependent signaling. The Journal of Biological Chemistry. 283: 24343-58. PMID 18614532 DOI: 10.1074/Jbc.M803444200 |
0.782 |
|
2008 |
Hamed H, Mitchell C, Park MA, Hanna D, Martin AP, Harrison B, Hawkins W, Curiel DA, Fisher PB, Grant S, Yacoub A, Hagan MP, Dent P. Human chorionic gonadotropin (hCG) interacts with lovastatin and ionizing radiation to modulate prostate cancer cell viability in vivo. Cancer Biology & Therapy. 7: 587-93. PMID 18379195 DOI: 10.4161/Cbt.7.4.5543 |
0.773 |
|
2008 |
Yacoub A, Hamed H, Emdad L, Dos Santos W, Gupta P, Broaddus WC, Ramakrishnan V, Sarkar D, Shah K, Curiel DT, Grant S, Fisher PB, Dent P. MDA-7/IL-24 plus radiation enhance survival in animals with intracranial primary human GBM tumors. Cancer Biology & Therapy. 7: 917-33. PMID 18376144 DOI: 10.4161/Cbt.7.6.5928 |
0.648 |
|
2008 |
Hamed H, Hawkins W, Mitchell C, Gilfor D, Zhang G, Pei XY, Dai Y, Hagan MP, Roberts JD, Yacoub A, Grant S, Dent P. Transient exposure of carcinoma cells to RAS/MEK inhibitors and UCN-01 causes cell death in vitro and in vivo. Molecular Cancer Therapeutics. 7: 616-29. PMID 18347148 DOI: 10.1158/1535-7163.Mct-07-2376 |
0.746 |
|
2008 |
Yacoub A, Gupta P, Park MA, Rhamani M, Hamed H, Hanna D, Zhang G, Sarkar D, Lebedeva IV, Emdad L, Koumenis C, Curiel DT, Grant S, Fisher PB, Dent P. Regulation of GST-MDA-7 toxicity in human glioblastoma cells by ERBB1, ERK1/2, PI3K, and JNK1-3 pathway signaling Molecular Cancer Therapeutics. 7: 314-329. PMID 18281516 DOI: 10.1158/1535-7163.Mct-07-2150 |
0.637 |
|
2008 |
Yacoub A, Park MA, Gupta P, Rahmani M, Zhang G, Hamed H, Hanna D, Sarkar D, Lebedeva IV, Emdad L, Sauane M, Vozhilla N, Spiegel S, Koumenis C, Graf M, et al. Caspase-, cathepsin-, and PERK-dependent regulation of MDA-7/IL-24-induced cell killing in primary human glioma cells. Molecular Cancer Therapeutics. 7: 297-313. PMID 18281515 DOI: 10.1158/1535-7163.Mct-07-2166 |
0.668 |
|
Show low-probability matches. |